FAS and cancer: This mechanism of action involved a raft-mediated activation of apoptosis via Fas/CD95, independently of its physiological FasL/CD95L ligand, which could be pharmacologically modulated, thus opening a new therapeutic approach in cancer therapy [1,27,34,35,53,59,64].